Schwantes-An TH, et al. - In view of the association of elevated serum concentrations of fibroblast growth factor 23 (FGF23) with cardiovascular mortality in patients with chronic kidney disease and those undergoing dialysis, researchers tested their hypothesis that polymorphisms in FGF23, its co-receptor alpha-klotho (KL), and/or FGF23 receptors (FGFR) are associated with cardiovascular events and/or mortality. From the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events Trial, in which patients were randomized to the calcimimetic cinacalcet or placebo for the treatment of secondary hyperparathyroidism, they used 1,494 DNA samples collected at baseline. Further, an analysis of European and African Ancestry samples was done separately and then summary statistics were combined to perform a meta-analysis. Outcomes revealed an association of rs11063112 with heart failure [HF] and cardiovascular mortality in patients receiving dialysis with moderate to severe secondary hyperparathyroidism.